Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.[1][2][3]
In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770million.[4] The acquisition completed in November 2022.[5]
External links
References
- Wallace Witkowski. Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results Fox Business, 16 September 2015^
- Josh Beckerman. Aerie Pharmaceuticals Shares Rise on Trial Results Wall Street Journal, 16 September 2015^
- Aerie Pharma shares battered as eye drug fails study Reuters, 23 April 2015, retrieved 7 January 2016^
- Alcon buys the American Aerie Pharmaceuticals for 770 million Swissinfo, 23 August 2022^
- Zac Ezzone. Durham loses public company HQ with Alcon-Aerie deal complete American City Business Journals, 23 November 2022^